Protherics plc (PTIL)

[surf1944]

Protherics PLC announces Research Update
Wednesday August 6, 2:20 am ET

CHESHIRE, UK--(MARKET WIRE)--Aug 6, 2008 --

Protherics PLC

DEEP results in pre-eclampsia to be presented at leading conference

London, UK; Brentwood, TN, US; 6 August 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, today announces that data
from the "DEEP" study has been selected as one of the
key presentations at the 16th World Congress of The International
Society for the Study of Hypertension in Pregnancy (ISSHP) in
Washington DC, US 21-25 September 2008.


On 22 April Protherics announced that its placebo-controlled phase
2b Digibind® Efficacy Evaluation in Pre-eclampsia ("DEEP") study in
severe pre-eclampsia met one of its two primary endpoints. An abstract
of the study results prepared by Protherics and other stakeholders in
the programme has been selected by ISSHP for presentation at the
opening plenary session on 22 September 2008. In addition,
two abstracts describing research data supporting the mechanism of
action of Digoxin Immune Fabs (DIFs) in pre-eclampsia have also been
accepted for presentation. Please see the ISSHP's website for more
details: http://www.isshp2008-washington.org/


Dr Garrett K. Lam, lead clinical investigator on the DEEP
study commented, "The opportunity to present the results of the DEEP
study at the ISSHP's World Congress reflects the considerable
scientific and medical interest in this important study
in pre-eclampsia, as this is the first time a drug has shown a clinical
benefit towards improving an end organ function in pre-eclamptic
patients. This study will advance efforts to identify the underlying
cause(s) of this life-threatening condition."


Andrew Heath, CEO commented: "We are delighted that the DEEP study
results will be one of the leading presentations at this prestigious
meeting. Discussions with key stakeholders about how to progress this
important programme continue, and we are encouraged by the interest
shown in the programme to date. We expect to give a further update on
next steps towards the end of the year."


Protherics also announces today that a patent has been granted in
the US covering the use of DIFs, including Digibind® (GlaxoSmithKline)
and DigiFabTM, as a method for controlling pre-eclampsia and eclampsia.


http://biz.yahoo.com/iw/080806/0422406.html



surf's up......crikey